Evidence map›Paper›PMID 38531097›Full record

ArticleThe American journal of tropical medicine and hygiene2024

SARS-CoV-2 Seroprevalence and Vaccine Uptake among Pregnant Women at First Antenatal Care Visits in Malawi.

Lyson Tenthani, Victoria Seffren, Alinune Nathanael Kabaghe, Francis Ogollah, Monica Soko, Ruchi Yadav, Felix Kayigamba, Danielle Payne, Nellie Wadonda-Kabondo, Elizabeth Kampira and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lyson TenthaniICAP at Columbia University, International Programs - Malawi, Lilongwe, Malawi.
Victoria SeffrenMalaria Branch, Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Alinune Nathanael KabagheU.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.
Francis OgollahICAP at Columbia University, International Programs - Malawi, Lilongwe, Malawi.
Monica SokoBlantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.
Ruchi YadavMalaria Branch, Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Felix KayigambaICAP at Columbia University, International Programs - Malawi, Lilongwe, Malawi.
Danielle PayneU.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.
Nellie Wadonda-KabondoU.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.
Elizabeth KampiraU.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.
Tyson VolkmannU.S. President's Malaria Initiative, U.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.
Nandita S SugandhiICAP at Columbia University, New York, New York.
Karl SeydelBlantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.
Eric RogierMalaria Branch, Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Julie I ThwingMalaria Branch, Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Julie R GutmanMalaria Branch, Division of Parasitic Diseases and Malaria, National Center for Emerging and Zoonotic Infectious Diseases, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many SARS-CoV-2 infections are asymptomatic, thus reported cases underestimate actual cases. To improve estimates, we conducted surveillance for SARS-CoV-2 seroprevalence among pregnant women attending their first antenatal care visit (ANC1) from June 2021 through May 2022. We administered a questionnaire to collect demographic, risk factors, and COVID-19 vaccine status information and tested dried blood spots for SARS-CoV-2 antibodies. Although <1% of ANC1 participants reported having had COVID-19, monthly SARS-CoV-2 seroprevalence increased from 15.4% (95% CI: 10.5-21.5) in June 2021 to 65.5% (95% CI: 55.5-73.7) in May 2022. Although COVID-19 vaccination was available in March 2021, uptake remained low, reaching a maximum of 9.5% (95% CI: 5.7-14.8) in May 2022. Results of ANC1 serosurveillance provided prevalence estimates helpful in understanding this population case burden that was available through self-report and national case reports. To improve vaccine uptake, efforts to address fears and misconceptions regarding COVID-19 vaccines are needed.

Indexed as

COVID-19COVID-19 VaccinesPregnancy Complications, InfectiousPrenatal CareSARS-CoV-2AdolescentAdultAntibodies, ViralFemaleHumansMalawiPregnancyPregnant PeopleSeroepidemiologic StudiesVaccinationYoung AdultAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID38531097
PMCPMC11066362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.